All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, March 5, 2021
Home » Blogs » BioWorld Perspectives » Cancer Research Through Time: Cure Should’ve Been Wrapped up by 1985

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

Cancer Research Through Time: Cure Should’ve Been Wrapped up by 1985

April 8, 2013
By Anette Breindl
No Comments

If you’re looking for a plenary speaker, pick a Pulitzer Prize winner. That was one of the corollary lessons to be had from the talk of Columbia University’s Siddhartha Mukherjee at the American Association for Cancer Research’s Annual Meeting on Sunday, which was somewhat like a Cliff Notes version of his Pulitzer-Prize winning epic on cancer, “The Emperor of all Maladies.”

Mukherjee regaled the audience with an apocryphal tale of a historian who was asked to predict the future of the Soviet Union and answered that “in the Soviet Union, the future is quite easy to predict. The problem is the past. The past keeps changing.”

That problem, he said, is also one in cancer research – faced with a cancer cell, we have ever-changing notions of how it got to be that way. Mukherjee traced the dominant theory of cancer’s natural history from the 1860s, when Rudolf Virchow first argued that dysregulated cell division is the root cause of cancer, to the notion now taking root that cancer is an organismal disease that involves changes to the microenvironment and the immune system of the cancer patient as well as to the genes and genomes that make up the cancerous cells.

Along the way, he shared fascinating stories of cancer and its treatments. The first chemotherapy was a chemical cousin of notorious World War I weapon mustard gas; pioneering surgeon and Johns Hopkins University co-founder William Halsted was addicted to both cocaine and morphine, which in his day was used to treat cocaine addiction; in the 1960s, philanthropist and medical research champion Mary Lasker thought that the cancer problem would be wrapped up by 1985.

At BioWorld, we’ve recommended The Emperor of all Maladies before, of course. It’s too much in our sweet spot not to. But good advice never gets old, and so if you have not read the book, it is still worth heading to your local bookstore, or library, and picking up a copy.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 4.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 4.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing